Clinically important drug interactions with disease-modifying antirheumatic drugs

Drugs and Aging

Volumn 13, Issue 4, 1998, Pages 281-289

  Haagsma, Cees J ^a,b  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b TWENTEBORG HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLOROQUINE; CISAPRIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450; DILTIAZEM; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; RIFAMPICIN; SALAZOSULFAPYRIDINE; TRIMETHOPRIM; VERAPAMIL;

HUMAN; KIDNEY FUNCTION; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

ANTIRHEUMATIC AGENTS; DRUG INTERACTIONS; HUMANS; RHEUMATIC DISEASES;

EID: 0031786158     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199813040-00004     Document Type: Review

References (55)

1. Pincus T. Long-term outcomes in rheumatoid arthritis. Br J Rheumatol 1994; 34 Suppl. 2: 59-73
2. Borgini MJ, Pualus HE. Combination therapy. In: Brook PM, Furst DE, editors. Innovative treatment approaches for rheumatoid arthritis. Ballieres Clin Rheumatol 1995; 9: 689-710
3. Bannwarth B, Pehourcq F, Scaeverbeke T, et al. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996; 30: 194-210
4. Rooney RW, Furst DE, Koehnke R, et al. Aspirin is not associated with more toxicity than other NSAIDs in patients with RA treated with methotrexate. J Rheumatol 1993; 20: 1297-302
5. Van de Putte, van Riel PLCM. Do disease-modifying antirheumatic drugs actually modify disease course in rheumatoid arthritis? Clin Immunother 1994; 1: 319-22
6. Morand EF, McCloud PI, Littlejohn GO. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol 1992; 19: 704-8
7. Situnayake RD, Grindulis KA, McConkey B. Long term treatment of rheumatoid arthritis with suphasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis 1987; 46: 177-83
8. Tett SE. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet 1993; 25: 392-407
9. Barrera P, Boerbooms AMT, van de Putte LBA, et al. Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum 1995; 25: 234-53
10. Seideman P, Albertoni F, Beck O, et al. Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1994; 37: 830-3
11. Seideman P, Kindstrom B. Pharmacokinetic interactions of penicillamine in rheumatoid arthritis. J Rheumatol 1989; 16: 473-4
12. Leden I. Digoxin-hydroxychloroquine interaction. Acta Med Scand 1982; 211: 411-2
13. Ette EI, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol 1987; 27: 813-6
14. El-Yazigi A, Wahab FA. Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. J Clin Pharmacol 1993; 33: 522-6
15. Barrera P, Boerbooms AMTh, Janssen EM, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993; 36: 1070-9
16. Zimm S, Collins JM, O'Neill D, et al. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983; 34: 810-6
17. Calabresi P, Chabner BA. Antineoplastic agents. In: Goodman Gilman A, Rall TW, Nies AS, et al., editors. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: McGraw-Hill Inc., 1993
18. Loadman PM, Bibby MC. Pharmacokinetic drug interactions with anticancer drugs. Clin Pharmacokinet 1994; 26: 486-500
19. Adkins JC, Peters DH, Markham A. Fludarabine: an update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53 (6): 1005-37
20. Jain J, McCaffrey PG, Miner Z, et al. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 1993; 365: 352-5
21. Somerville MF, Scott DGI. Neoral-new cyclosporin for old? Br J Rheumatol 1997; 36: 1113-5
22. Turgeon DK, Leichtman AB, Lown KS. P450 3A activity and cyclosporin dosing in kidney and heart transplant recipients. Clin Pharmacol Ther 1994; 56: 253-60
23. Tugwell P, Bombardier C, Gent M, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335: 1051-5
24. Campana C, Regazzi MB, Buggia I, et al. Clinically significant drug interactions with cyclosporin. Clin Pharmacokinet 1996; 30: 141-79
25. Chitwood KK, Abdul-Haqq AJ, Heim-Duthoy KL. Cyclosporine-amiodarone interaction. Ann Pharmacother 1993; 27: 569-71
26. Ducharma MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporin after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57: 485-91
27. Grekas D, Nikolaidis P, Karamonzis M, et al. Effects of azathioprine on cyclosporin metabolism. Nephron 1992; 60: 489
28. Yussim A, Bar-Nathan N, Shaharabani E, et al. Gastrointestinal, hepatorenal, and neuromuscular toxicity caused by cyclosporine-colchicine interaction in renal transplantation. Transplant Proc 1994; 26: 2825-6
29. Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, et al. Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases. Br J Rheumatol 1997; 36: 1095-9
30. Smith PJ, Swinburn WR, Swinson DR, et al. Influence of previous gold toxicity on subsequent development of penicillamine toxicity. BMJ 1982; 285: 595-6
31. Fort JG, Abruzzo JL. Nitritoid reaction following initiation of ACE inhibitors in patients with rheumatoid arthritis treated with im gold [abstract]. Arthritis Rheum 1992; 35 Suppl.: R10
32. Jeurissen ME, Boerbooms AM, van de Putte LB. Pancytopenia and methotrexate with trimethoprim-sulphamethoxazole [letter]. Ann Intern Med 1989; 111: 261
33. Ng HWK, MacFarlane AW, Graham RM, et al. Near fatal drug interactions with methotrexate given for psoriasis [letter]. BMJ 1987; 295: 752-3
34. Lilly MB, Omura GA. Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid. Cancer Chemother Pharmacol 1985; 15: 220-2
35. Morgan SL, Babott JE, Vaugh WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double blind, placebo-controlled trial. Ann Intern Med 1994; 121: 833-41
36. Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of a randomised, double-blind, placebo-controlled trial. Arthritis Rheum 1993; 35: 795-803
37. Bannwarth B, Labat L, Moride Y, et al. Methotrexate in rheumatoid arthritis. Drugs 1994; 47 (1): 25-50
38. Seideman P, Albertioni F, Beck O, et al. Chloroquine reduces bioavailability of methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1994; 37: 830-3
39. Netter P, Bannwarth B, Pere P, et al. Clinical pharmacokinetics of D-penicillamine. Clin Pharmacokinet 1987; 13: 317-33
40. Hoffman BF, Bigger JT. Digitalis and allied cardiac glycosides. In: Goodman Gilman A, Rall TW, Nies AS et al., editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 816
41. Bourge RC. Cardiac transplantation. In: Bennet JC, Plum F, editors. Cecil textbook of medicine. 20th ed. Philadelphia: WB Saunders, 1996: 365-6
42. Billaud EM, Guillemain R, Fortineau N. et al. Interaction between roxithromycin and cyclosporin in heart transplant patients. Clin Pharmacokinet 1990; 19: 499-502
43. Kessler M, Netter F, Zerrouki M. Spiramycin does not increase plasma cyclosporine concentrations in renal transplant patients. Eur J Clin Pharmacol 1988; 35: 331-2
44. Blocka K. Auranofin versus injectable gold: comparison of pharmacokinetic properties. Am J Med 1983; 75: 114-22
45. Tishler M, Caspi D, Fishel B, et al. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum 1988; 31: 906-8
46. Erttmann R, Landbeck G. Effect of oral cholestyramine on the elimination of high-dose methotrexate. J Cancer Res Clin Oncol 1985; 110: 48-50
47. Fries J, Singh G, Lenert L, et al. Aspirin, hydroxychloroquine and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 1990; 33: 1611-9
48. Ferraz MB, Pinheiro, GRC, Helfenstein M, et al. Combination therapy with methotrexate and chloroquine in rheumatoid arthritis: a randomized, placebo-controlled trial. Scand J Rheumatol 1994; 23: 231-6
49. Millard RJ, McCredie S. Bladder cancer in patients on low-dose methotrexate and corticosteroids. Lancet 1994; 343: 1222-3
50. Ferracoli GF, Casatta L, Bartoli E, et al. Epstein-Barr virus-associated Hodgkin's lymphoma in a rheumatoid arthritis patient treated with methotrexate and cyclosporin A. Arthritis Rheum 1995; 38: 867-8
51. Taggart AJ, McDermott BJ, Roberts SD. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis. Clin Pharmacokinet 1992; 23: 311-20
52. Smedegård G, Björk J. Sulphasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumtol 1995; 34 Suppl. 2:7-15
53. Bird HA. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid: which is the active moiety in rheumatoid arthritis? Br J Rheumatol 1995; 34 Suppl. 2: 16-9
54. Awni WM, Braeckman RA, Locke CS, et al. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and n-acetylsulfapyridine. Clin Pharmacokinet 1995; 29 Suppl. 2: 98-104
55. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 456-9